In early 2026, the emergence of oral Janus kinase inhibitors like brepocitinib and filgotinib is providing a major breakthrough for patients who prefer systemic oral therapy over frequent intraocular injections. These 2026 small-molecule inhibitors work by blocking the JAK and TYK2 signaling pathways, effectively suppressing a broad range of pro-inflammatory cytokines that contribute to macular...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china